



GENERICS AND BIOSIMILAR MEDICINES DELIVER MORE SAVINGS EVERY YEAR

At a moment when policymakers are contemplating measures to reduce drug prices for America's patients, AAM's 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, breaks the savings down by state, age, payer, common medical conditions and more.

Because tens of millions of Americans entrust their health to generics and biosimilars, they saved \$338 billion in 2020, and nearly \$2.4 trillion in the last decade.

HEALTH CARE SYSTEM SAVINGS

2020 U.S. Generic & Biosimilar Savings: **\$338 Billion**

93% of Generic Prescriptions Are Filled for **\$20** or Less



Generics represent **90%** of prescriptions filled, yet account for only **18%** of prescription drug spending

Generic 10-year savings: **nearly \$2.4 trillion**

Nearly **four billion** generic and biosimilar prescriptions are dispensed each year

Generics represent only **3%** of all health care spending

2021 Savings to Medicare: \$109.6 Billion

Average Generic Copay: **\$6.61**


Average Brand-Name Copay: **\$55.82**

Good News for Seniors and Taxpayers

Without generic competition, Medicare drug spending would have been almost double its current level.

Medicaid savings came to **\$53.8 billion** in 2020.

The amount paid at the pharmacy counter is what matters to patients. High prices can discourage patients from following their prescriptions. Fortunately, **93%** of the time, the copay for a generic prescription is under **\$20**.



Biosimilar Savings: \$7.9 Billion

To date, the FDA has approved 31 biosimilars across 11 molecules. Twenty biosimilars are on the market, with prices that average 30% less than their reference brand biologic. At least six more biosimilars are scheduled to come to market in 2023. This competition has lowered costs for both the reference products and their biosimilars. Since their introduction, biosimilars have been used in more than 121 million days of patient therapy and have supported almost 10 million incremental days of therapy.

Source: IQVIA, National Sales Perspectives, Dec 2020